Country's largest drug maker Ranbaxy Laboratories Ltd today announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech Pvt Ltd.
BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio generic product, the company said in a filing to the Bombay Stock Exchange.
Presently, Osteoporosis segment in India has a market size of around Rs 219 crore and it is growing at the rate of more than 29 per cent per annum.
The product has been indigenously researched at 'Virchow Biotech and developed with aid from the Department of Science and Technology under the Indian Government.
"Bonista is also a classic example of our endeavours to offer quality bio-generic therapeutic options to doctors and an affordable and efficacious product to patients," Ranbaxy Senior Vice President & Regional Director (Asia & CIS) Sanjeev I Dani said.
He said, "Ranbaxy has a number of new products in its pipeline, including 'Bonista', for the Osteoporosis patients who are normally treated by orthopaedics and gynecologists."
Osteoporosis is highly prevalent in India and according to an estimated 61 million people in India are reported to be affected by it, Ranbaxy said.
Virchow Biotech, part of the Hyderabad-based Rs 600 crore Virchow Group, engaged in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generic products.plements its manifesto, both at the national and the constituency levels."